Northeast Financial Consultants Inc Lineage Cell Therapeutics, Inc. Transaction History

Northeast Financial Consultants Inc

  • $2.16 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021
SELL
$0.95 - $1.83 $497,568 - $958,473
-523,756 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$0.54 - $1.01 $91,854 - $171,801
-170,100 Reduced 24.52%
523,756 $466,000
Q3 2019

Nov 13, 2019
BUY
$0.85 - $1.24 $589,777 - $860,381
693,856 New
693,856 $680,000

Others Institutions Holding LCTX

# of Institutions
121
Shares Held
94.3M
Call Options Held
31.3K
Put Options Held
400
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $154M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Northeast Financial Consultants Inc Portfolio

Follow Northeast Financial Consultants Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northeast Financial Consultants Inc, based on Form 13F filings with the SEC.

News

Stay updated on Northeast Financial Consultants Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email